



LUND UNIVERSITY

Synthesis and characterisation of novel platinum-based drug candidates

Bjelosevic, Haris; Sykfont Snygg, Åse; Spegel, Christer; Gorton, Lo; Elmroth, Sofi; Persson, Tina

2006

[Link to publication](#)

Citation for published version (APA):

Bjelosevic, H., Sykfont Snygg, Å., Spegel, C., Gorton, L., Elmroth, S., & Persson, T. (2006). *Synthesis and characterisation of novel platinum-based drug candidates*. Abstract from 37th International Coordination Chemistry Conference (ICCC), Cape Town, South Africa.

Total number of authors:

6

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY


PO Box 117
221 00 Lund
+46 46-222 00 00

Synthesis and characterisation of novel platinum-based drug candidates

Haris Bjelosevic^a, Åse Sykfont Snygg^b, Christer Spégel^c,
Lo Gorton^c, Sofi K. C. Elmroth^b and Tina Persson^a

^aOrganic chemistry; ^bBiochemistry; ^cAnalytical chemistry

^{a,b,c}Department of Chemistry, Lund University, P.O. Box 124, Lund, SE-22100, Sweden
e-mail: Haris.Bjelosevic@organic.lu.se



Introduction

Cisplatin, *cis*-Pt(NH₃)₂Cl₂ (*cis*-diamminedichloroplatinum(II)) was introduced in the clinic around 1980. Its use as a chemotherapeutic agent has been particularly successful in the treatment of testicular and ovarian cancers. The cytotoxicity of cisplatin is thought to be related to its ability to modify nuclear DNA.^{1,2} Unfortunately, factors such as toxic side effects and development of drug resistance in tumors limit the use of the drug. Therefore, there is a great interest in developing new Pt-based drug candidates with improved clinical efficacy and reduced toxicity.

In this study, we have synthesised derivatives of 1,1'-bis(diphenylphosphino)-ferrocene (dppf) and their corresponding *cis*-platinum complexes (Fig. 1). Earlier studies have shown that some dppf-based platinum complexes exhibit promising antineoplastic and antimicrobial activity.^{3,4} Our ambition is to improve water solubility as well as reactivity profile of this class of compounds. The long term goal is to obtain substances which allow for more specific interaction patterns towards biological targets.







Fig. 1: Synthesised platinum compounds used in kinetic studies

Synthesis

Compound (±)-*N,N*-dimethyl-1-ferrocenylethylamine was used as starting material (Scheme 1). First, the primary amine **4** was produced in three steps,⁵ whereupon the succinamic acid linker was attached to the amino functionality to produce compound **5** (Scheme 1). Following, compound **5** was reacted with 5-(aminopropynyl)uridine **9** resulting in compound **10** (Scheme 2).⁶ Compounds **2**, **3**, **6** and **10** were reacted with (1,5-cyclooctadiene)platinum(II)chloride, [PtCl₂(cod)], to produce the platinated compounds **11-14** (Scheme 3).



Cyclic voltammetry measurements

The CV of dppf contains two sets of redox reactions, those of the ferrocene moiety and those of the phosphino groups. The CV of [PtCl₂(dppf)] and compounds **11-14** contains only one set of redox waves, with a considerably higher formal potential (E^0) in comparison with that of uncoordinated dppf ($E^0 = 390$ mV vs dppf).

Modification of the cyclopentadienyl ring resulted in an increased i_c/i_a ratio, which probably depends on the electron donating ability of the substituent. The three substituted compounds **11**, **12** and **13** showed no significant difference in electrochemical behaviour.

Voltammogram of complex **14** showed that the peak current of the reduction wave of the ferrocene moiety is larger than for the corresponding oxidation - the narrow shape and sweep rate dependence suggest that the oxidised species might be adsorbed on the electrode whereas the reduced species is dissolved.




Fig. 2: CV voltammograms

Kinetic studies




Fig. 3: Selected HPLC chromatograms, comp. 14

Compounds **12** and **13** were further investigated by studying their reactivity towards L-cysteine and L-methionine.⁷ In addition, compound **14** was tested for its reactivity using DNA as target.⁶ In this study, two types of oligomers were used, one containing the GG sequence, d(T₇GGT₇), and the other containing the slightly more reactive phosphorothioate group d(T₆p(S)T₆).

Figure 3 shows selected HPLC chromatograms at different reaction times illustrating the platination of d(T₆p(S)T₆). The two diastereomers of the unplatinated oligonucleotides are eluting at $t_r \sim 8$ and $t_r \sim 9$ min, and the product peaks start to elute at $t_r \sim 16$ min. The inserted graph displays the fit of a single exponential function to normalised, integrated peak areas versus time for the unplatinated oligonucleotide. Reaction conditions: [Pt(II)] = 1.0×10^{-5} M, [d(T₆p(S)T₆)] = 2.0×10^{-6} M, [Na⁺] = 10.0 mM.

Conclusions

Compounds **12** and **13** showed increased reactivity towards L-cys and L-met compared to dppf and cisplatin. The proposed mechanism involves establishment of a hydrogen bond between the substituent and the entering ligand, and subsequent outer-sphere complex stabilisation. Compound **14** showed reactivity similar to cisplatin towards selected oligonucleotides.

Ref.: [1] B. Rosenberg, *Plat. Met. Rev.* **15**, 42 (1971); [2] J.M. Pascoe and J.J. Roberts, *Biochem. Pharmacol.* **23**, 1345 (1974); [3] V. Scarcia, A. Furlani, B. Longato, B. Corain and G. Pilloni, *Inorg. Chim. Acta* **153**, 67 (1988); [4] R.W. Mason, K. McGrouther, P.R. Ranatunge-Bandarage, B.H. Robinson and J. Simpson, *Appl. Organomet. Chem.* **13**, 163 (1999); [5] T. Hayashi, T. Miese, M. Fukushima, M. Kagotani, N. Nagashima, Y. Hamada, A. Matsumoto, S. Kawakami, M. Konishi, K. Yamamoto and M. Kumada, *Bull. Chem. Soc. Jpn.* **53**, 1138 (1980); [6] H. Bjelosevic, C. Spégel, Å. Sykfont Snygg, L. Gorton, S.K.C. Elmroth and T. Persson, *Tetrahedron* **62**, 4519 (2006); [7] G. Puxty, H. Bjelosevic, T. Persson and S.K.C. Elmroth, *Dalton Trans.* **18**, 3032 (2005).

